Full video transcriptClick to expand
Auto-generated transcript of @clareedgar6's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Hi here is a little update on my switch from Minjaro to Wigouve, what I thought about it, and
- 0:06obviously with the price increases I
- 0:08stopped for five weeks. I took nothing and then I decided to try
- 0:13Wigouve, even though I had seen mixtures on TikTok,
- 0:17one word, rubbish,
- 0:20absolutely rubbish, has done nothing for me whatsoever, so I had gained weight
- 0:28by stopping any GLP one for about five weeks, and
- 0:33then I got the one MG on this, I was on 10 of Minjaro, so I got the one MG on this,
- 0:40equivalent to 7.5,
- 0:43was actually very nervous to take it because I thought I've took nothing for five weeks,
- 0:46I'm going straight on to with like a 7.5 to one MG in Mugouve, and
- 0:51I'm gonna be so nauseous, I'm not gonna be able to eat, I might be crampy,
- 0:55I might be running into the toilet, all these things, but injected anyway because I was just increasing
- 1:01point after point, and
- 1:04No, done nothing, absolutely nothing, didn't suppress my appetite, didn't make me feel fuller, quicker,
- 1:11didn't stop me thinking about food, didn't do anything, it was like injecting water, nothing, and I don't know whether it's just because I've been on
- 1:18Minjaro, but I just continued to gain weight, this was 140 pounds, so that was 140 pounds down the drain.
- 1:25So anyway, I'm back on to Minjaro, I ordered it from
- 1:30Chekup, my checkup, checkup, something like that, and I got a 50 point off code,
- 1:37and I managed to get the 10 milligram for 220,
- 1:41so I've got that, and then I had a bit of extra money because,
- 1:45I had a bit of extra money that I would like to spend on instead of Christmas,
- 1:50so I also bought a 12.5 pound ahead of time, all
- 1:56Juniper,
- 1:57so that was to, again with a code, so that was
- 2:01265 point, which is mental, like it is so dear, but you know what, I came with skills, I
- 2:07was really surprised with that, I thought that was brilliant, and I wondered why the box is so big and I arrived,
- 2:12I know it works, and I feel like, if you're paying for some of them, it might as well work,
- 2:20you know, there's no point in paying for a govie, 140 pound, because it's cheaper, but it does absolutely nothing.
- 2:27Anyway, that's just what's happened to me, I don't know if the same has happened to you,
- 2:33now that I've got like 10 weeks worth with the golden doses, I'm kind of hoping in that time,
- 2:39I'll get codes and be able to buy more, I would really like to be on until the summer,
- 2:47but yeah, let me know what happened with you.
GLP-1 weight loss claims on TikTok: separating fact from hype
Quick answer
This creator discontinued tirzepatide (Mounjaro 10mg) for five weeks due to cost, experienced weight regain consistent with published GLP-1 discontinuation data, then switched to semaglutide (Wegovy 1mg) with no perceived effect before returning to tirzepatide sourced via a third-party platform. Her subjective non-response to semaglutide following prolonged tirzepatide use is anecdotal but not clinically implausible given the different receptor profiles of the two drugs. No clinician guidance on switching protocol or re-titration is mentioned at any point in the video.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 weight loss claims on TikTok: separating fact from hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 weight loss claims on TikTok: separating fact from hype" from Clare Edgar596. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This creator discontinued tirzepatide (Mounjaro 10mg) for five weeks due to cost, experienced weight regain consistent with published GLP-1 discontinuation data, then switched to semaglutide (Wegovy 1mg) with no perceived effect before returning to tirzepatide sourced via a third-party platform.
The reason this review is not generic is the source wording and the canonical claim label "glp1 glp1 wegovy mounjaroprescription mounjaro juniper." In this clip, the useful excerpt is: "Hi here is a little update on my switch from Minjaro to Wigouve, what I thought about it, and obviously with the price increases I stopped for five weeks." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This creator discontinued tirzepatide (Mounjaro 10mg) for five weeks due to cost, experienced weight regain consistent with published GLP-1 discontinuation data, then switched to semaglutide (Wegovy 1mg) with no perceived effect before returning to tirzepatide sourced via a third-party platform.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This creator discontinued tirzepatide (Mounjaro 10mg) for five weeks due to cost, experienced weight regain consistent with published GLP-1 discontinuation data, then switched to semaglutide (Wegovy 1mg) with no perceived effect before returning to tirzepatide sourced via a third-party platform. Her subjective non-response to semaglutide following prolonged tirzepatide use is anecdotal but not clinically implausible given the different receptor profiles of the two drugs. No clinician guidance on switching protocol or re-titration is mentioned at any point in the video.
- SURMOUNT-5 (2024) found tirzepatide produced roughly 47% greater weight loss than semaglutide head-to-head, so the preference for Mounjaro over Wegovy has real trial data behind it.
- There is no validated dose conversion between tirzepatide and semaglutide. Describing 1mg semaglutide as equivalent to 7.5mg tirzepatide is not supported by any published clinical guidance.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- SURMOUNT-5 (2024) found tirzepatide produced roughly 47% greater weight loss than semaglutide head-to-head, so the preference for Mounjaro over Wegovy has real trial data behind it.
- There is no validated dose conversion between tirzepatide and semaglutide. Describing 1mg semaglutide as equivalent to 7.5mg tirzepatide is not supported by any published clinical guidance.
- Rubino et al. (2021, JAMA) showed GLP-1 discontinuation leads to significant weight regain within weeks to months, consistent with what this creator experienced after her five-week break.
- Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates GLP-1 only. They are pharmacologically distinct drugs, not interchangeable versions of the same treatment.
- Individual response to semaglutide varies. The STEP 1 trial (Wilding et al., 2021, NEJM) showed mean weight loss of nearly 15% on semaglutide 2.4mg, meaning many patients do respond well to it.
- Switching between GLP-1 medications after a break typically requires re-titration from a lower starting dose. Whether 1mg semaglutide was a therapeutically adequate comparison point after being off all GLP-1 for five weeks is a clinical question, not a TikTok one.
- Sourcing prescription GLP-1 medications through discount codes across multiple third-party platforms raises legitimate concerns about supply chain integrity, cold storage compliance, and product authenticity.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @clareedgar6 actually say?
After stopping GLP-1 medication for five weeks due to price increases, @clareedgar6 switched from tirzepatide (Mounjaro) to semaglutide (Wegovy), starting at 1mg. She describes it as "like injecting water" with zero appetite suppression, no food noise reduction, and continued weight gain. She spent £140 on Wegovy, saw no results, and has since returned to tirzepatide, sourcing it from a service called Checkup and also purchasing through Juniper with a discount code.
She also describes injecting what she frames as a 7.5mg tirzepatide equivalent dose after a five-week break, having been on 10mg previously, and says she expected severe side effects but experienced none.
Does the science back this up?
There is legitimate clinical evidence that tirzepatide produces greater weight loss than semaglutide, so her experience is not scientifically implausible. But calling Wegovy "rubbish" for everyone oversimplifies a more complicated picture.
The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced mean weight loss of around 20.9% of body weight. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced approximately 14.9% mean weight loss. Head-to-head data from the SURMOUNT-5 trial (2024) confirmed tirzepatide outperformed semaglutide in direct comparison, with roughly 47% more weight loss at the highest doses. So the gap is real and documented.
However, "done nothing" is a strong claim. Individual response varies considerably. Some patients do respond strongly to semaglutide, particularly those who have not previously been on tirzepatide. The issue she may be experiencing is tolerance or desensitisation from prior tirzepatide exposure, not a universal failure of semaglutide.
What did they get wrong (or right)?
She got the general direction right: tirzepatide does tend to outperform semaglutide in clinical trials. She deserves credit for being honest about weight regain during her five-week break, which is consistent with what studies show about GLP-1 discontinuation.
Where she goes wrong is in her dose equivalency framing. She says 1mg Wegovy is "equivalent to 7.5" of Mounjaro. This is not an established clinical conversion. Semaglutide and tirzepatide work through different mechanisms. Tirzepatide is a dual GIP and GLP-1 receptor agonist; semaglutide is a GLP-1 receptor agonist only. You cannot map one dose onto the other as equivalents. That framing is misleading and should not be repeated as fact.
She also does not mention that starting any GLP-1 after a five-week gap typically requires re-titration from a lower dose, meaning 1mg semaglutide may have been an appropriate starting point, not a direct comparison to her previous 10mg tirzepatide.
What should you actually know?
If you are considering switching between GLP-1 medications, there are a few things worth knowing before you spend £140 based on TikTok feedback.
- Tirzepatide and semaglutide are not interchangeable by dose. They bind to different receptors and have different mechanisms. There is no validated dose conversion chart between them.
- Weight regain after stopping GLP-1 treatment is well-documented. The STEP 4 trial (Rubino et al., 2021, JAMA) showed participants regained about two-thirds of lost weight within a year of stopping semaglutide. A five-week gap is enough to see meaningful regain, as this creator experienced.
- Individual response to semaglutide versus tirzepatide varies. The population averages from SURMOUNT-5 do not predict your personal outcome. Some people respond well to semaglutide; others respond better to tirzepatide.
- Sourcing GLP-1 medications from discount codes and multiple platforms raises questions about supply chain, cold storage, and whether you are receiving genuine licensed product. This is not a minor concern.
- Any switch between GLP-1 medications should involve a prescribing clinician, not a TikTok comment section.
The bottom line
@clareedgar6 is describing a real phenomenon that has some clinical backing: tirzepatide does produce greater average weight loss than semaglutide in trials. Her personal experience, while frustrating, is plausible. But her claim that Wegovy is universally ineffective, combined with inaccurate dose equivalency framing, is the kind of content that nudges viewers toward medication decisions without the full picture. The science says tirzepatide tends to win on average. It does not say semaglutide is water.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Clare Edgar596 · TikTok creator
12.3K views on this video
#glp1 #wegovy #mounjaroprescription #mounjaro #juniper
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about surmount-5 (2024) found tirzepatide produced roughly 47% greater weight loss?
SURMOUNT-5 (2024) found tirzepatide produced roughly 47% greater weight loss than semaglutide head-to-head, so the preference for Mounjaro over Wegovy has real trial data behind it.
What does the video say about there?
There is no validated dose conversion between tirzepatide and semaglutide. Describing 1mg semaglutide as equivalent to 7.5mg tirzepatide is not supported by any published clinical guidance.
What does the video say about rubino et al. (2021, jama) showed glp-1 discontinuation leads to?
Rubino et al. (2021, JAMA) showed GLP-1 discontinuation leads to significant weight regain within weeks to months, consistent with what this creator experienced after her five-week break.
What does the video say about tirzepatide activates both gip?
Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates GLP-1 only. They are pharmacologically distinct drugs, not interchangeable versions of the same treatment.
What does the video say about individual response to semaglutide varies. the step 1 trial (wilding?
Individual response to semaglutide varies. The STEP 1 trial (Wilding et al., 2021, NEJM) showed mean weight loss of nearly 15% on semaglutide 2.4mg, meaning many patients do respond well to it.
What does the video say about switching between glp-1 medications after a break typically requires re-titration?
Switching between GLP-1 medications after a break typically requires re-titration from a lower starting dose. Whether 1mg semaglutide was a therapeutically adequate comparison point after being off all GLP-1 for five weeks is a clinical question, not a TikTok one.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Clare Edgar596, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.